title: Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy.
abstract: Hyperlipidemia worsens diabetic nephropathy, although the mechanism by which renal lipids accumulate is unknown. We previously demonstrated that renal proteoglycans have high low-density lipoprotein (LDL) binding affinity, suggesting that proteoglycan-mediated LDL retention may contribute to renal lipid accumulation. The aim of this study was to determine the relative effect of diabetes and hyperlipidemia on renal proteoglycan content. Diabetic and non-diabetic LDL receptor-deficient mice were fed diets containing 0% or 0.12% cholesterol for 26 weeks, and then kidneys were analyzed for renal lipid and proteoglycan content. Diabetic mice on the high-cholesterol diet had accelerated development of diabetic nephropathy with elevations in urine albumin excretion, glomerular and renal hypertrophy, and mesangial matrix expansion. Renal lipid accumulation was significantly increased by consumption of the 0.12% cholesterol diet, diabetes, and especially by both. The renal proteoglycans biglycan and decorin were detectable in glomeruli, with a significant increase in renal biglycan content in diabetic mice on the high-cholesterol diet. Renal biglycan and renal apolipoprotein B were colocalized, and regression analyses showed a significant relation between renal biglycan and renal apolipoprotein B content. The increased renal biglycan content in diabetic nephropathy probably contributes to renal lipid accumulation and the development of diabetic nephropathy.
authors: Department of Veterans Affairs, Lexington, Kentucky, USA.
authors: Joel
authors: J
authors: Thompson
authors: Patricia
authors: P
authors: Wilson
authors: Katie
authors: K
authors: Brandewie
authors: Deepa
authors: D
authors: Taneja
authors: Liliana
authors: L
authors: Schaefer
authors: Bonnie
authors: B
authors: Mitchell
authors: Lisa R
authors: LR
authors: Tannock
mesh_terms: D000419:Albuminuria / Q000209:etiology; D000818:Animals; D001055:Apolipoproteins B / Q000378:metabolism; D058578:Biglycan / Q000378:metabolism*; D015153:Blotting, Western; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D003928:Diabetic Nephropathies / Q000209:etiology* / Q000378:metabolism; D005260:Female; D006949:Hyperlipidemias / Q000378:metabolism; D007668:Kidney / Q000378:metabolism*; D007678:Kidney Glomerulus / Q000378:metabolism; D050356:Lipid Metabolism; D008077:Lipoproteins, LDL / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D011509:Proteoglycans / Q000378:metabolism*; D011973:Receptors, LDL / Q000378:metabolism
chemical_list: D001055:Apolipoproteins B; D058578:Biglycan; D002791:Cholesterol, Dietary; D008077:Lipoproteins, LDL; D011509:Proteoglycans; D011973:Receptors, LDL